Hyderabad-based pharmaceutical company Aurobindo Pharma announced today that it has received the tentative approval to manufacture and market Nevirapine tablets for oral suspension 50mg from the US Food and Drug Administration (USFDA).
The new drug application (NDA) 22-299 provides for the use Nevirapine in combination with other antiretrovirals agents and is indicated for the treatment of HIV infections, stated a release from the company.
The company has a total of 113 NDA approvals, including 84 final approvals and 29 tentative approvals from the USFDA.
